Add BrightSurf on Google Email

Beth Israel Deaconess Medical Center


Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

Researchers at Beth Israel Deaconess Medical Center discovered that specific genetic events drive distinct immune cell compositions in primary prostate tumors, dictating tumor progression and response to therapy. Profiling patients' tumors based on this new information could lead to more successful clinical trials and tailored therapies.

SourceBeth Israel Deaconess Medical Center·JournalNature Medicine·DateJan 12, 2018

Can brain lesions contribute to criminal behavior?

Research reveals that brain lesions affecting a specific network involved in moral decision-making are more common among individuals exhibiting criminal behavior. This finding highlights the potential link between brain dysfunction and crime, but also emphasizes that genetic, environmental, and social factors play important roles.

SourceBeth Israel Deaconess Medical Center·JournalProceedings of the National Academy of Sciences·DateDec 18, 2017

BIDMC researchers use artificial intelligence to identify bacteria quickly and accurately

Researchers at BIDMC used AI to develop an automated microscope system that can quickly and accurately identify images of bacteria, reducing the reliance on human clinical microbiologists. The system achieved nearly 95% accuracy in identifying three types of bacteria, paving the way for a future diagnostic platform.

SourceBeth Israel Deaconess Medical Center·JournalJournal of Clinical Microbiology·DateDec 15, 2017

One in six patients with PAD who undergo revascularization readmitted within 30 days

A study of nearly 62,000 hospitalizations found that 17.6% of PAD patients were readmitted within 30 days after revascularization procedures, with complications being the primary cause of readmission for 30% of cases. Strategies to prevent readmissions focus on high-risk patients with PAD and improving post-procedure care.

SourceBeth Israel Deaconess Medical Center·JournalAnnals of Internal Medicine·DateDec 4, 2017

Study shows epidurals don't slow labor

A new study published in Obstetrics & Gynecology has found that epidural analgesia does not affect the duration of the second stage of labor, contrary to long-held beliefs. The research compared catheter-infused epidural anesthetic with a saline placebo and found no significant difference in duration or other outcomes.

SourceBeth Israel Deaconess Medical Center·JournalObstetrics and Gynecology·DateOct 10, 2017

Scientists catalogue 'parts list' of brain cell types in a major appetite center

Researchers have cataloged 50 distinct cell types in a major appetite center of the brain, including two newly discovered subtypes that play a role in genetic control of obesity. The study provides a comprehensive parts list for this area of the brain, allowing researchers to identify which cells are responsible for specific functions.

SourceBeth Israel Deaconess Medical Center·JournalNature Neuroscience·DateFeb 6, 2017

Hospital-led interventions associated with significant reduction in cesarean rate

A new study at Beth Israel Deaconess Medical Center found that hospital-led interventions significantly reduced the Cesarean delivery rate from 34.8% to 21.2% over a seven-year period. The interventions included quality improvement measures such as standardized protocols, increased provider education and revised guidelines.

SourceBeth Israel Deaconess Medical Center·JournalThe Joint Commission Journal on Quality and Patient Safety·DateJan 26, 2017

Study: Hospital readmission rates decrease after passage of ACA financial penalties

A new analysis found that hospitals with high readmission rates for Medicare patients with certain health conditions saw significant decreases after the passage of the Affordable Care Act's Hospital Readmissions Reduction Program. The poorest performing hospitals achieved the greatest reductions in readmission rates, suggesting that fi...

SourceBeth Israel Deaconess Medical Center·JournalAnnals of Internal Medicine·DateDec 26, 2016

Personalized cancer vaccine is associated with promising outcomes for patients with AML

A personalized cancer vaccine significantly improved outcomes for patients with acute myeloid leukemia (AML) in a clinical trial, showing protection from relapse in most patients and minimal side effects. The vaccine stimulated powerful immune responses against AML cells, using the body's own defense systems to fight cancer.

SourceBeth Israel Deaconess Medical Center·JournalScience Translational Medicine·DateDec 7, 2016